of Cancer 2017, 5:53 
 
  10. Y. Zhu, B. L. Knolhoff, M. A. Meyer et al. CSF1/CSF1R Blockade reprograms 
      tumor-infiltrating macrophages and improves response to T cell checkpoint 
      immunotherapy in pancreatic cancer models. Cancer Research 2014 (74), 
      5057-5069 
 
  11. E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages impede CD8 T cells 
      from reaching tumor cells and limit the efficacy of anti--PD-1 treatment. 
      Proceedings of the National Academy of Science of the United States of 
      America 2018 (115), E4041-E4050 
 
  12. V. Mazzaferro, B. F. El-Rayes, M. Droz dit Busset et al. Derazantinib 
      (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive 
      intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120), 
      165-171. ClinicalTrials.gov-Identifier: NCT01752920 
 
  13. FIDES-01: ClinicalTrials.gov-Identifier: NCT03230318 
 
  14. FIDES-02: ClinicalTrials.gov-Identifier: NCT04045613

Anhang 


   -- Pressemitteilung (PDF) 
      https://ml-eu.globenewswire.com/Resource/Download/2dffc515-7a3a-4759-834e-363a069be8e6

(END) Dow Jones Newswires

October 11, 2021 01:15 ET (05:15 GMT)